Sarepta Therapeutics to Request Expansion of Elevidys to All Age Groups Following Study Results
By Denny Jacob
Sarepta Therapeutics said it will request expanding its Duchenne muscular dystrophy treatment to patients in all age groups following results of a study.
The commercial-stage biopharmaceutical company said study participants treated with Elevidys showed an increase on the North Star Ambulatory Assessment, a measure of motor function, compared to placebo-treated patients at 52 weeks, although the primary endpoint wasn't met.
Sarepta said the study of Elevidys supports the conclusion that the treatment modifies the trajectory of people dealing with Duchenne. The Phase 3 clinical study of Elevidys evaluated the treatment in patients with Duchenne between the ages of four and seven.
Elevidys received accelerated FDA approval for patients ages four through five in June.
Based on the results of the study, "we intend to move swiftly to request an update to expand the labeled indication to treat all patients," said Chief Executive Doug Ingram. He added that the leadership at the Food and Drug Administration confirmed that, based on the evidence so far, they are open to such an expansion if supported by a review of the data.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
October 30, 2023 17:02 ET (21:02 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks